Tenax Therapeutics, Inc.
TENXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. With a market capitalization of $72.6M, it sits in micro-cap territory. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Market Cap
$72.6M
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
-1.29
EPS (TTM)
$-1.48
EPS (Fwd)
$-1.50
ROE
-59.8%
ROA
-37.7%
Cash
$118.0M
Total Debt
$0
Free CF
-$24.0M
52W Change
-67.7%
Annual Financials
Cash vs Debt
Where TENX stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, TENX finished 84.91% below its 150-day moving average ($12.19) and 84.65% below its 200-day moving average ($11.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TENX overbought or oversold?
At the September 1, 2026 close, TENX's RSI(14) was 55.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tenax Therapeutics, Inc. reports $118.0M in cash and $0 in total debt. Free cash flow is running at -$24.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -59.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tenax Therapeutics, Inc. and its sector.